Loading...
•
Sep 30, 2024
Artivion Q3 2024 Earnings Report
Artivion's financial performance showed revenue growth and progress in R&D initiatives.
Key Takeaways
Artivion reported a 9% increase in revenue compared to Q3 2023, driven by growth in key product lines and geographic regions. The company achieved several R&D milestones, including regulatory approval for BioGlue in China and submission of the first module of the PMA application for AMDS with the FDA. The company is narrowing its revenue guidance and continues to expect constant currency revenue growth of between 10% to 12% for the full year 2024 compared to 2023 and now expects a range of $389 to $396 million for 2024 compared to the previously articulated range of $388 to $396 million.
Total revenues for the third quarter of 2024 were $95.8 million, an increase of 9% on a GAAP basis and 10% on a non-GAAP constant currency basis, both compared to the third quarter of 2023.
Net loss for the third quarter of 2024 was ($2.3) million, or ($0.05) per fully diluted common share.
Non-GAAP net income for the third quarter of 2024 was $5.0 million, or $0.12 per fully diluted common share.
Artivion is narrowing its revenue guidance and continues to expect constant currency revenue growth of between 10% to 12% for the full year 2024 compared to 2023 and now expects a range of $389 to $396 million for 2024 compared to the previously articulated range of $388 to $396 million.
Forward Guidance
Artivion is narrowing its revenue guidance and continues to expect constant currency revenue growth of between 10% to 12% for the full year 2024 compared to 2023 and now expects a range of $389 to $396 million for 2024 compared to the previously articulated range of $388 to $396 million. Additionally, Artivion continues to expect adjusted EBITDA growth of between 28% and 34% for the full year 2024 compared to 2023 resulting in an expected range of $69 to $72 million for 2024.
Positive Outlook
- Expect constant currency revenue growth of between 10% to 12% for the full year 2024 compared to 2023.
- Expect a range of $389 to $396 million for 2024 compared to the previously articulated range of $388 to $396 million.
- Expect negligible year-over-year currency impact on the full year 2024 revenues.
- Expect adjusted EBITDA growth of between 28% and 34% for the full year 2024 compared to 2023.
- Expect a range of $69 to $72 million for 2024 in adjusted EBITDA.
Challenges Ahead
- The Company's financial performance for 2024 and future periods is subject to risks.
- Unpredictability of the timing and outcome of regulatory decisions.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...